Stanford phd candidate Calvin schmidt posts about investing opportunities in synthetic biology. Available for consulting on potential investments in this area.

Calvin Schmidt Synthetic Biology Index: May Update

Performance overview
Value at beginning of month: $96,196.79
Value at end of month: $95,584.27
Month over month change: -0.64%
Total CAGR: -10.12%
 
Related indices, monthly change
NASDAQ: +4.27%
IVV (iShares Core S&P 500): +2.54%
IBB (iShares NASDAQ Biotechnology Index): -0.62%
MXI (iShares Global Materials): +1.64%
VEGI (iShares MSCI Global Agriculture Producers): +1.83%
 
Individual performances

A few chemicals companies had massive losses, led by Amyris when they announced an new equity investment of $35M. These companies dragged the index to a loss in May, but gains from Intrexon and Novozymes helped limit losses.
 
Changes made to index
 
None
 
Allocation as of June 3, 2017

Calvin Schmidt Synthetic Biology Index: June Update

Calvin Schmidt Synthetic Biology Index: April Update